Drug Trial Radar · NCT07117669
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Dec 16, 2025
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- N-Fold, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- CBCC Global Research
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
Conditions
- Peanut Allergy
Interventions
ENP-501Drug
* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose
PlaceboDrug
* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
- Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
- Number of Participants with Dose Limiting Toxicities (DLTs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
- Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
- Number of Participants with changes in Clinical Laboratory Values in Part 1Time frame: Up to 22 Weeks
- Number of Participants with changes in Physical Examination in Part 1Time frame: Up to 22 Weeks
- Number of Participants with changes in Vital Signs in Part 1Time frame: Up to 22 Weeks
- Proportion of Participants Tolerating ≥1043 mg Cumulative Peanut Protein Without Dose-Limiting Symptoms at End of Treatment (EOT) Visit Double-Blind Placebo-Controlled Food Challenge (DBPCFC) Compared to Placebo in Part 2Time frame: Up to 72 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site 001
Aurora, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.